Post Subject #1088   BMY’s lineup at ASCO and EHA: DewDiligence 05/19/22 08:23:03 AM #1087   Opdivo/Yervoy failed to show statsig-superior OS compared to DewDiligence 05/16/22 02:38:41 PM #1085   BMY buys worldwide commercial rights to BBIO’s BBP-398: DewDiligence 05/12/22 11:35:24 AM #1084   BMY extends/expands drug-discovery collaboration with EVO: DewDiligence 05/10/22 12:18:07 PM #1083   1Q22 CC transcript: DewDiligence 04/29/22 04:08:42 PM #1082   BMY 1Q22 results: DewDiligence 04/29/22 08:07:34 AM #1081   FDA approves BMY’s Camzyos (mavacamten) for obstructive hypertrophic cardiomyopa DewDiligence 04/28/22 09:06:35 PM #1080   Looks like it's starting to rollover. Cosa 04/22/22 04:19:37 PM #1079   NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures DewDiligence 04/14/22 05:23:59 PM #1078   BMY presents full dataset from CHECKMATE-816 trial in DewDiligence 04/11/22 12:01:42 PM #1077   EU approves three new Opdivo indications… DewDiligence 04/05/22 03:41:32 PM #1076   Updated Cumulative Results Of Treatment With Mavacamten lettruthringout 04/03/22 01:21:49 PM #1075   Certainly BMY never would've parted with China franchise. lettruthringout 04/02/22 05:14:43 PM #1074   … [BMY] may be eligible to receive regulatory DewDiligence 04/02/22 03:04:58 PM #1073   LianBio might be better play for mavacamten lettruthringout 04/02/22 02:55:53 PM #1072   BMY’s reports detailed Mavacamten data from phase-3 VALOR trial: DewDiligence 04/02/22 01:22:19 PM #1071   I just grabbed a few puts for September. Cosa 03/25/22 03:49:28 PM #1070   Reblozyl sBLA in beta thalassemia PDUFA extended three DewDiligence 03/25/22 08:59:44 AM #1069   BMY inks oncology-drug-discovery collaboration with (private) Volastra Therapeut DewDiligence 03/21/22 12:38:48 PM #1068   Addendum—BMY has projected $4B+ peak sales of Opdualag DewDiligence 03/19/22 01:44:51 PM #1067   FDA approves Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma DewDiligence 03/19/22 01:39:54 PM #1066   BMY sues AZN claiming Imfinzi infringes Opdivo patent: DewDiligence 03/18/22 02:12:49 PM #1065   Keytruda monotherapy-vs-placebo DFS HR=0.76 in adjuvant* NSCLC, irrespective DewDiligence 03/17/22 05:08:22 PM #1064   NKTR’s Bempeg fails as addend to Opdivo in DewDiligence 03/14/22 09:56:49 AM #1063   TEVA launches first US generic Revlimid—but the generic DewDiligence 03/07/22 03:09:49 PM #1062   FDA approves Opdivo/chemo in neoadjuvant* NSCLC, irrespective of DewDiligence 03/04/22 08:25:05 PM #1061   Opdivo sBLA in resectable NSCLC has 7/13/22 PDUFA DewDiligence 02/28/22 10:24:36 AM #1060   BHVN licenses SMA drug candidate—taldefgrobep alfa (a/k/a BMS-986089) DewDiligence 02/25/22 11:31:20 AM #1059   CHMP approves three new Opdivo indications with PD-L1 DewDiligence 02/25/22 11:29:35 AM #1058   Mavacamten phase-3 succeeds in patients with obstructive HCM DewDiligence 02/16/22 10:32:17 AM #1057   BMY sells $6B of 10-40yr notes: DewDiligence 02/15/22 06:29:58 PM #1056   BMY executes $5B ASR* agreements, following through on DewDiligence 02/09/22 08:02:43 AM #1055   BMY 4Q21 results… DewDiligence 02/04/22 08:11:00 AM #1053   CHMP approves Breyanzi for second-line lymphomas: DewDiligence 01/28/22 09:43:52 AM #1052   BMY JPM slides in .pdf format: DewDiligence 01/10/22 02:22:40 PM #1051   BMY, IPSC ink drug-discovery collaboration: DewDiligence 01/10/22 11:34:15 AM #1050   BMY issues 2022 non-GAAP EPS guidance of $7.65-7.95—starts DewDiligence 01/10/22 11:31:02 AM #1048   Retiring 11% of the outstanding shares of such biotech_researcher 01/02/22 03:28:38 PM #1047   FDA approves BMY’s Orencia for prevention of graft-versus-host DewDiligence 12/15/21 12:07:20 PM #1046   BMY takes global license to IMTX’s TCR-bispecific program—$150M up-front: DewDiligence 12/14/21 10:02:47 AM #1045   GILD vs BMY in LBCL CAR-T—who has the edge? DewDiligence 12/13/21 07:03:57 PM #1044   BMY boosts dividend—authorizes $15B share buyback: DewDiligence 12/13/21 09:47:30 AM #1043   Reblozyl sBLA in beta thalassemia—>3/27/22 PDUFA date—(with FDA DewDiligence 12/03/21 09:08:46 AM #1042   Being destroyed like the micro cap biotechs… puzzling.. biotech_researcher 11/29/21 10:23:27 AM #1041   Deucravacitinib for psoriasis has 9/10/22 PDUFA date (with DewDiligence 11/29/21 10:12:44 AM #1040   Mavacamten PDUFA extended 3mo to 4/28/22: DewDiligence 11/19/21 09:12:59 AM #1039   BMY Investor Day slides (140 pages): DewDiligence 11/16/21 09:14:34 AM #1038   BMY presents phase-2 Milvexian data at AHA: DewDiligence 11/15/21 11:40:34 AM #1037   BMY reports statsig DFS in neoadjuvant* NSCLC: DewDiligence 11/08/21 09:41:32 AM #1036   BMY’s AHA lineup: DewDiligence 11/08/21 09:35:36 AM Post Subject

© 2022 InvestorsHub.com, Inc.